Literature DB >> 33719090

Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).

Amandeep Salhotra1, Ahmed Aribi1, Dat Ngo2, Jianying Zhang3, Karamjeet Sandhu1, Monzr Al-Malki1, Haris Ali1, Paul Koller1, Shukaib Arslan1, Elizabeth Budde1, Samer Khaled1, Sanjeet Dadwal4, David S Snyder1, Andrew Artz1, Stephen Forman1, Ryotaro Nakamura1, Anthony Stein1, Guido Marcucci1, Ibrahim Aldoss1, Vinod Pullarkat1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33719090     DOI： 10.1002/ajh.26157

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  2 in total

1.  Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.

Authors:  Andrew H Matthews; Alexander E Perl; Selina M Luger; Alison W Loren; Saar I Gill; David L Porter; Daria V Babushok; Ivan P Maillard; Martin P Carroll; Noelle V Frey; Elizabeth O Hexner; Mary Ellen Martin; Shannon R McCurdy; Edward A Stadtmauer; Vikram R Paralkar; Ximena Jordan Bruno; Wei-Ting Hwang; David Margolis; Keith W Pratz
Journal:  Blood Adv       Date:  2022-07-12

2.  Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.

Authors:  Nicholas J Short; Sangeetha Venugopal; Wei Qiao; Tapan M Kadia; Farhad Ravandi; Walid Macaron; Courtney D Dinardo; Naval Daver; Marina Konopleva; Gautam Borthakur; Elizabeth J Shpall; Uday Popat; Richard E Champlin; Rohtesh Mehta; Gheath Al-Atrash; Betul Oran; Elias Jabbour; Guillermo Garcia-Manero; Ghayas C Issa; Guillermo Montalban-Bravo; Musa Yilmaz; Abhishek Maiti; Hagop Kantarjian
Journal:  J Hematol Oncol       Date:  2022-01-29       Impact factor: 17.388
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.